Leidos Holdings Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Leidos Holdings Inc (LDOS). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q2 2025 | Q3 2025 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|
| Intelligence & Digital | $1.40B 33.0% | $1.39B 32.9% | $1.50B 34.2% | $1.49B 32.7% |
| Health | $1.18B 28.0% | $1.17B 27.6% | $1.19B 27.1% | $1.09B 23.9% |
| Homeland | $769.0M 18.2% | $771.0M 18.2% | $815.0M 18.6% | $1.02B 22.4% |
| Defense | $879.0M 20.8% | $899.0M 21.2% | $883.0M 20.1% | $955.0M 21.0% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | Q2 2025 | Q3 2025 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|
| United States | $3.88B 91.8% | $3.89B 92.0% | $4.03B 91.9% | $4.14B 91.1% |
| International | $347.0M 8.2% | $340.0M 8.0% | $357.0M 8.1% | $404.0M 8.9% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Remaining performance obligations
Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.
| As of | Remaining performance obligations |
|---|---|
| Q3 2026 | $20.00B |
| Q2 2026 | $19.00B |
| Q1 2026 | $18.50B |
| Q4 2025 | $17.00B |
| Q3 2025 | $16.00B |
| Q2 2025 | $17.00B |
| Q1 2025 | $16.30B |
| Q3 2024 | $16.00B |
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 10, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.